 | Up a level |
Grebely, Jason; Dalgard, Olav; Conway, Brian; Cunningham, Evan B; Bruggmann, Philip; Hajarizadeh, Behzad; Amin, Janaki; Bruneau, Julie; Hellard, Margaret; Litwin, Alain H; Marks, Philippa; Quiene, Sophie; Siriragavan, Sharmila; Applegate, Tanya L; Swan, Tracy; Byrne, Jude; Lacalamita, Melanie; Dunlop, Adrian; Matthews, Gail V; Powis, Jeff; ... (2018). Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. The lancet. Gastroenterology & hepatology, 3(3), pp. 153-161. Elsevier 10.1016/S2468-1253(17)30404-1
Grebely, Jason; Dalgard, Olav; Cunningham, Evan B; Hajarizadeh, Behzad; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Amin, Janaki; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Hellard, Margaret; Bruneau, Julie; Midgard, Håvard; ... (2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. The international journal of drug policy, 47, pp. 177-186. Elsevier 10.1016/j.drugpo.2017.05.020
Cunningham, Evan B; Hajarizadeh, Behzad; Dalgard, Olav; Amin, Janaki; Hellard, Margaret; Foster, Graham R; Bruggmann, Philip; Conway, Brian; Backmund, Markus; Robaeys, Geert; Swan, Tracy; Marks, Philippa S; Quiene, Sophie; Applegate, Tanya L; Weltman, Martin; Shaw, David; Dunlop, Adrian; Bruneau, Julie; Midgard, Håvard; Bourgeois, Stefan; ... (2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC infectious diseases, 17(1), p. 420. BioMed Central 10.1186/s12879-017-2517-3
